- Home
- FMAO vs SKYE Comparison
FMAO vs SKYE Comparison
Compare FMAO & SKYE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMAO
- SKYE
- Stock Information
- Founded
- FMAO 1897
- SKYE 2012
- Country
- FMAO United States
- SKYE United States
- Employees
- FMAO N/A
- SKYE N/A
- Industry
- FMAO Savings Institutions
- SKYE Biotechnology: Pharmaceutical Preparations
- Sector
- FMAO Finance
- SKYE Health Care
- Exchange
- FMAO Nasdaq
- SKYE Nasdaq
- Market Cap
- FMAO 290.9M
- SKYE 108.3M
- IPO Year
- FMAO N/A
- SKYE N/A
- Fundamental
- Price
- FMAO $27.39
- SKYE $4.78
- Analyst Decision
- FMAO Hold
- SKYE Buy
- Analyst Count
- FMAO 2
- SKYE 6
- Target Price
- FMAO $26.00
- SKYE $18.67
- AVG Volume (30 Days)
- FMAO 17.0K
- SKYE 330.3K
- Earning Date
- FMAO 10-28-2024
- SKYE 11-09-2024
- Dividend Yield
- FMAO 3.16%
- SKYE N/A
- EPS Growth
- FMAO N/A
- SKYE N/A
- EPS
- FMAO 1.56
- SKYE N/A
- Revenue
- FMAO $95,411,000.00
- SKYE N/A
- Revenue This Year
- FMAO N/A
- SKYE N/A
- Revenue Next Year
- FMAO $7.89
- SKYE N/A
- P/E Ratio
- FMAO $18.03
- SKYE N/A
- Revenue Growth
- FMAO N/A
- SKYE N/A
- 52 Week Low
- FMAO $16.90
- SKYE $1.44
- 52 Week High
- FMAO $28.76
- SKYE $19.41
- Technical
- Relative Strength Index (RSI)
- FMAO 52.40
- SKYE 53.92
- Support Level
- FMAO $25.93
- SKYE $3.53
- Resistance Level
- FMAO $28.76
- SKYE $4.53
- Average True Range (ATR)
- FMAO 0.64
- SKYE 0.41
- MACD
- FMAO 0.11
- SKYE 0.15
- Stochastic Oscillator
- FMAO 57.19
- SKYE 100.00
About FMAO Farmers & Merchants Bancorp Inc.
Farmers & Merchants Bancorp Inc is a holding company for Farmers & Merchants Bank of Central California. The company is engaged in general commercial banking business. The activities of the company include commercial, agricultural and residential mortgages as well as consumer and credit card lending activities.
About SKYE Skye Bioscience Inc. Common Stock
Skye Bioscience Inc is a pre-clinical pharmaceutical company located in San Diego, California. The company's clinical assets focus on the modulation of cannabinoid receptor 1 ("CB1") to provide novel treatments and alternatives for diseases caused by metabolic disorders, inflammation, fibrosis and neurodegeneration, such as obesity and glaucoma. The company's Phase 2 clinical candidates include nimacimab, a negative allosteric modulating antibody that inhibits peripheral CB1 receptors, currently being developed for the treatment of obesity and SBI-100 Ophthalmic Emulsion ("SBI-100 OE"), a CB1 agonist (activator), currently being developed for the treatment of glaucoma and ocular hypertension.